New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
10:03 EDTLG, PAL, FEYE, WBC, HUBG, LLY, ONNN, VIPS, WWWW, NKE, HAR, ALGT, CACI, GEVA, YELP, MNK, EL, ARMHOn The Fly: Analyst Upgrade Summary
ARM Holdings (ARMH) upgraded to Market Perform from Underperform at Bernstein... Allegiant Travel (ALGT) upgraded to Buy from Hold at Deutsche Bank... Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital... Estee Lauder (EL) upgraded to Outperform from Market Perform at Bernstein... Harman (HAR) upgraded to Strong Buy from Outperform at Raymond James...Hub Group (HUBG) upgraded to Buy from Hold at BB&T... Mallinckrodt (MNK) upgraded to Outperform from Market Perform at BMO Capital... Nike (NKE) upgraded to Buy from Hold at Stifel... S Ecology (ECOL) upgraded to Buy from Hold at KeyBanc... WABCO (WBC) upgraded to Conviction Buy from Buy at Goldman... Yelp (YELP) upgraded to Buy from Neutral at SunTrust... Web.com (WWWW) upgraded to Buy from Hold at Craig-Hallum... FireEye (FEYE) upgraded at Wedbush... Synageva (GEVA) upgraded at Wedbush... Vipshop (VIPS) upgraded to Outperform from Neutral at Credit Suisse... North American Palladium (PAL) upgraded to Sector Performer at CIBC... CACI International (CACI) upgraded to Outperform from Underperform at Raymond James... ON Semiconductor (ONNN) upgraded to Buy from Neutral at MKM Partners... Laclede (LG) upgraded to Buy from Hold at Stifel.
News For ARMH;ALGT;LLY;EL;HAR;HUBG;MNK;NKE;WBC;YELP;WWWW;FEYE;GEVA;VIPS;PAL;CACI;ONNN;LG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 27, 2015
10:00 EDTYELPOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
09:32 EDTFEYEFireEye should report strong Q4 results, says Wells Fargo
Wells Fargo believes that FireEye benefited last quarter from strong demand for advanced malware detection solutions and good demand for its endpoint product. The firm is confident that the company's Q4 billings can meet or exceed the consensus outlook of $203M. It keeps an Outperform rating.
05:32 EDTYELPYelp upgraded to Outperform from Market Perform at Raymond James
January 26, 2015
10:19 EDTELHigh option volume stocks
High option volume stocks: OIL NFX ABB FXCM SANM EL MAT AGO NPSP SSTK
07:36 EDTGEVASynageva announecs dosing of patients concerned with SBC-103 in Phase 1/2 study
Synageva announced dosing with SBC-103 in patients with mucopolysaccharidosis IIIB has begun as part of a Phase 1/2 study. In addition, the FDA recently granted SBC-103 Fast Track designation. The trial will enroll approximately nine patients, two years of age or greater but less than 12 years of age, with definitive diagnosis of MPS IIIB and developmental delay. Patients will be treated in one of three different dosing cohorts with every other week intravenous administrations of SBC-103 for 24 weeks. Patients who meet qualifying criteria may continue therapy with SBC-103 for an extended treatment period that will last up to 128 weeks. The primary endpoint of the trial is safety and tolerability of intravenous administration of SBC-103 in patients with MPS IIIB. The study will also determine the effects of dosing with SBC-103 on the onset, magnitude, and reversibility of changes in levels of total HS in cerebral spinal fluid, serum, and urine as well as measure the effects of neurocognitive and developmental function and change in brain structures as assessed by magnetic resonance imaging. Exploratory biomarkers, SBC-103 concentration in CSF, MPS IIIB disease characteristics, symptoms, and quality of life will also be measured.
January 23, 2015
12:39 EDTNKElululemon rises after JPMorgan analyst says EPS can more than double
Subscribe for More Information
07:04 EDTMNKMallinckrodt board approves share repurchase program
Mallinckrodt announced that its board has approved a share repurchase program. The open-ended authorization permits the company to repurchase up to $300 million of Mallinckrodt ordinary shares.
06:36 EDTNKElululemon upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded lululemon (LULU) to Overweight saying its recent field work has indicated positive traffic and demand trends while management is laying the foundation for sustainable growth. The firm raised its price target for shares to $75 from $50. The retailer of athletic apparel closed yesterday up 90c to $63.76. JPMorgan notes that its $75 price target reflects a 20% discount to peers Nike (NKE) and Under Armour (UAUA).
January 22, 2015
08:16 EDTHARHarman to acquire Symphony Teleca for base purchase price of $780M
Subscribe for More Information
08:14 EDTHARHarman to acquire Red Bend Software for $170M
Subscribe for More Information
07:42 EDTFEYEIT security demand very strong, says Wells Fargo
Subscribe for More Information
06:32 EDTYELPBlue Calypso files motion to lift stay in patent infringement cases and appeal
Blue Calypso (BCYP) announced that it has filed a motion in the Eastern District of Texas to lift the negotiated stay on the pending patent infringement litigation between the Company and Groupon (GRPN), Yelp (YELP), Foursquare and IZEA.PK. The Company has also filed notices of appeal at the Federal Circuit Court of Appeals in each of the Covered Business Method Review cases at the Patent Trial and Appeals Board. On January 14, 2014, the parties agreed to stay the litigation in the Eastern District pending the decisions from the PTAB as to validity of the patents. As a part of agreeing to join the stay, the parties jointly agreed to ask the Court to lift the stay and for an expedited litigation schedule if any of the asserted claims were held valid by the PTAB. The PTAB now has confirmed the validity of twenty-eight claims and Blue Calypso, through its counsel, has asked the Court to lift the stay according to the agreement. The defendants refused to participate in the motion to lift the stay as previously agreed, and have instead asked the Court to leave the stay in place in a separate motion.
06:24 EDTFEYEJPMorgan downgrades three in Software, FireEye a top pick
Subscribe for More Information
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
10:01 EDTELOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:44 EDTARMHARM Holdings upgraded to Buy from Neutral at Citigroup (yesterday)
Subscribe for More Information
06:07 EDTELEstee Lauder downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
January 20, 2015
14:26 EDTARMHARM Holdings short bet increased by Einhorn, ValueWalk reports
Subscribe for More Information
07:03 EDTHARCEVA-Harman FANCI Project granted funding from Horizon 2020
Subscribe for More Information
January 19, 2015
12:39 EDTFEYEFireEye achieves certification within UK Cyber Essentials Scheme
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use